IMPROVED DILUENT FOR VACCINE AGAINST CELL-ASSOCIATED ALPHA-HERPESVIRUS Russian patent published in 2022 - IPC A61K39/255 A61K39/12 A61P31/12 

FIELD: biotechnology.

SUBSTANCE: present invention relates to the use of a diluent for the stabilization during use of cells infected by cell-associated alpha-herpesvirus. In contrast to the long-established practice of including significant amount of peptone in a diluent composition for such virus-infected cells, it was found that the reduction in the amount of protein in the diluent improves the stability during use of cells infected by cell-associated alpha-herpesvirus. In this case, the better stability was achieved even in the use of a diluent that does not contain protein at all. This effect was especially expressed for recombinant HVT viruses expressing a heterologous insert.

EFFECT: absence of protein is very profitable for the production of a diluent in terms of costs, safety, and production stability.

8 cl, 7 ex, 5 tbl